何晓瑾辨治强直性脊柱炎生物制剂干预失败医案1则

谢岷株; 刘迎欣; 谢国倩; 何晓瑾

意见反馈

您当前的位置：

首页 >

文章列表页 >

何晓瑾辨治强直性脊柱炎生物制剂干预失败医案1则

中国中医药临床案例成果库 | 病例报告

上一篇: 国医大师包金山治疗左右两侧股骨骨折验案一则

下一篇: 中医药治疗宫颈鳞癌术后及放化疗后SCC升高1例

何晓瑾辨治强直性脊柱炎生物制剂干预失败医案1则
A Case of Failed Biologic Intervention for Ankylosing Spondylitis Differentiated and Treated by HE Xiaojin
1.南京中医药大学附属医院江苏省中医院风湿科，南京 210029
2.天津市滨海新区中医医院呼吸内科，天津 300450
DOI：

扫描看全文

谢岷株, 刘迎欣, 谢国倩, 等. 何晓瑾辨治强直性脊柱炎生物制剂干预失败医案1则[DB/OL].（2023-10-27）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43052697&Fpath=home&index=0

XIE Minzhu, LIU Yinxin, XIE Guoqian, et al. A Case of Failed Biologic Intervention for Ankylosing Spondylitis Differentiated and Treated by HE Xiaojin[DB/OL].（2023-10-27）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43052697&Fpath=home&index=0
谢岷株, 刘迎欣, 谢国倩, 等. 何晓瑾辨治强直性脊柱炎生物制剂干预失败医案1则[DB/OL].（2023-10-27）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43052697&Fpath=home&index=0 DOI：

XIE Minzhu, LIU Yinxin, XIE Guoqian, et al. A Case of Failed Biologic Intervention for Ankylosing Spondylitis Differentiated and Treated by HE Xiaojin[DB/OL].（2023-10-27）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43052697&Fpath=home&index=0 DOI：

摘要

病史摘要,2,患者乐某，男，23岁，2018年6月21日因“腰背部僵痛半年，加重2月”求诊。患者来诊时已确诊为“强直性脊柱炎”，并已在当地三甲医院行生物制剂治疗（注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白25mg皮下注射每周2次），效果不显，疼痛僵硬等症状仍进行性加重。患者考虑长期生物制剂治疗存在诱发感染、增加恶性疾病发生率及影响其他脏器功能等弊端，遂放弃西医治疗，经人介绍至何晓瑾教授门诊寻求中医治疗。何师以温肾强督，化痰逐瘀，通络止痛为大法，从肝脾肾三脏论治，收效颇丰，患者腰背疼痛从程度减轻到频次降低再到基本消失，何师从根本上改变了患者体质，实现了临床缓解。中医诊断　大偻肾虚督亏，痰瘀痹阻西医诊断　强直性脊柱炎干预措施　以温肾强督，化痰逐瘀，通络止痛之法拟方论治疗效转归　临床缓解

Abstract

Summary of case history,　Patient Le, male, 23 years old, sought medical attention on June 21, 2018, for "stiffness and pain in the lower back for six months, aggravated for two months". The patient had been diagnosed with "ankylosing spondylitis" at the time of consultation and had been treated with biologics (Recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein for injection 25mg subcutaneously twice a week) at a local tertiary care hospital, but the effect was not significant and the pain and stiffness continued to worsen progressively. The patient considered that long-term biologic treatment has the disadvantages of inducing infection, increasing the incidence of malignant disease, and affecting the function of other organs, so he gave up Western medical treatment and was referred to Professor He's clinic for Chinese medicine treatment. The patient's lower back pain was reduced from the degree to the frequency to the basic disappearance. Professor He fundamentally changed the patient's constitution and achieved clinical remission.TCM diagnosis　Dyphosis, Kidney deficiency and Du deficiency, Paralysis with phlegm and stagnation syndromeDiagnosis　Ankylosing spondylitisTherapeutic methods　To warm the kidneys and strengthen the Du, resolve phlegm and remove blood stasis, and relieve pain for the treatment of the proposed prescription.Clinical outcomes　clinical remission.

关键词

强直性脊柱炎大偻

Keywords

Ankylosing spondylitisDyphosis

references

黄烽,朱剑,王玉华,等.强直性脊柱炎诊疗规范[J].中华内科杂志,2022,61(08):893-900.

王志强,宫彩霞,李振彬.强直性脊柱炎病理性新骨形成机制研究进展[J].中国中医骨伤科杂志,2019,27(06):83-88.

赵琳茹,孔纯玉,李媛,等. 强直性脊柱炎的免疫学研究进展[J].国际生物医学工程杂志,2022,45(06):553-557,567.

王睿尧,康武林,秦鹏俊,熊慧敏.中西医治疗强直性脊柱炎的研究进展[J].世界中医药,2022,17(21):3107-3111.

国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994.

Linden S,Valkenburg H A,Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York Criteria[J]. Arthritis & Rheumatology,1984,27(4):361-368.

郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.

徐胜前,黄烽.强直性脊柱炎的达标治疗[J].中华内科杂志,2014,53(11):841-843.

Ruiz DE Morales J M G,Puig L,Daudén E,et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies[J]. Autoimmun Rev. 2020,19(1):102429.

Braun J,Baraliakos X,Deodhar A,et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase Ⅲ MEASURE 1 study[J]. Ann Rheum Dis,2017,76(6):1070-1077.

杨晓姣,周瑾,董艳,赵振宇.IL-17A抑制剂司库奇尤单抗和依奇珠单抗致不良反应文献分析[J].中国新药杂志,2022,31(10):1027-1032

Van der Heijde D,Baraliakos X,Sieper J,et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial[J]. Ann Rheum Dis. 2022,81(11):1515-1523.

潘彩彬,刘献祥.强直性脊柱炎之"偻痹"病名考[J].风湿病与关节炎,2015,4(4):57-59.

焦树德.大偻(强直性脊柱炎)病因病机及辨证论治探讨(下)[J].江苏中医药,2003,24(2):1.

杨学青,阎小萍.阎小萍教授对"和法"治疗强直性脊柱炎的认识及组方特色[J].中国临床医生,2012,40(11):70-73.

李时珍著. 本草纲目:第3卷[M]. 长春:吉林大学出版社, 2009:143.

张莉云,黄烽 . 生物制剂治疗强直性脊柱炎研究进展[J].中华风湿病学杂志,2005,9(2):112-115.

王莉沙,黄烽,张江林,等 . 肿瘤坏死因子拮抗剂在治疗强直性脊柱炎中的安全性分析[J]. 中国新药杂志 , 2007,16(7):556-561.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

六经辨治大偻（强直性脊柱炎）1例

中西医结合治疗强直性脊柱炎验案一则

阎小萍老师治疗强直性脊柱炎“治未病”学术思想的临床应用

汪悦治疗强直性脊柱炎经验

林昌松补肾祛瘀法论治强直性脊柱炎经验